Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.41 |
| ▸ | MRGPRX1 | Q96LB2 | 3/20 | 0.40 |
| ▸ | PPARG | P37231 | 2/20 | 0.39 |
| ▸ | PPARA | Q07869 | 2/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.36 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12778378 | 0.94 | NPC1 (0.45) | NPC1RAB9AKCNA5MRGPRX1PPARG | |
| SCHEMBL12778373 | 0.94 | MEN1 (0.40) | NPC1RAB9AKCNA5MRGPRX1PPARG | |
| SCHEMBL12778430 | 0.91 | NPC1 (0.42) | NPC1RAB9AKCNA5MRGPRX1PPARG | |
| SCHEMBL12778385 | 0.90 | L3MBTL1 (0.39) | NPC1RAB9AMRGPRX1PPARGPPARA | |
| SCHEMBL12778366 | 0.90 | CCR9 (0.42) | MRGPRX1PPARGPPARALMNAL3MBTL1 | |
| SCHEMBL12778369 | 0.89 | LMNA (0.43) | NPC1RAB9AMRGPRX1PPARGPPARA | |
| SCHEMBL12778760 | 0.88 | PTGS1 (0.43) | LMNAHTTSMN1; SMN2PTGS1PTGS2 | |
| SCHEMBL12778474 | 0.88 | NPC1 (0.46) | NPC1RAB9AMRGPRX1PPARACA12 | |
| SCHEMBL12778377 | 0.88 | POLB (0.39) | MRGPRX1PPARGPPARALMNAL3MBTL1 | |
| SCHEMBL12778427 | 0.88 | P2RX1 (0.40) | NPC1RAB9AMRGPRX1PTGS1PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7906538-B2 | Parasiticides; nematocides; crop protection | SCHERING-PLOUGH ANIMAL HEALTH CORPORATION (US) | 2011-03-15 | — | — | US | disclosed |
| US-20080262048-A1 | CONTROL OF PARASITES IN ANIMALS BY THE USE OF NOVEL TRIFLUOROMETHANESULFONANILIDE OXIME ETHER DERIVATIVES | SCHERING-PLOUGH ANIMAL HEALTH CORPORATION | 2008-10-23 | — | — | US | disclosed |
| US-7312248-B2 | Control of parasites in animals by the use of novel trifluoromethanesulfonanilide oxime ether derivatives | SCHERING-PLOUGH ANIMAL HEALTH CORPORATION (US) | 2007-12-25 | — | — | US | disclosed |
| US-7312248-B2 | Control of parasites in animals by the use of novel trifluoromethanesulfonanilide oxime ether derivatives | SCHERING-PLOUGH ANIMAL HEALTH CORPORATION (US) | 2007-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080262048-A1 | CONTROL OF PARASITES IN ANIMALS BY THE USE OF NOVEL TRIFLUOROMETHANESULFONANILIDE OXIME ETHER DERIVATIVES | TRHDE, EPX, EPHX1 | NPC1 4153/4885RAB9A 924/4885KCNA5 3249/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.